This modification enhances the binding of IGF2BP3 to m6A-modified PCK2 and NRF2 mRNAs, thereby significantly increasing their expression and promoting lenvatinib resistance in HCC [74]. Here, IGF2BP3 is linked to hepatocellular carcinoma.